Reneuron Share Discussion Threads

[joeblogg2] 13/5/2021 12:57

Brad. I have but this has certainly gone down more then others. RP study too early for result but hopefully early positive indications would be nice!!

[bradders51] 13/5/2021 10:26

joe. Have you not seen the majority of other share prices ??

[masingi] 13/5/2021 08:58

Bouncing off 150.

[joeblogg2] 13/5/2021 08:56

What is happening here , continued slide last few days!!

[brucie5] 05/5/2021 14:14

Looks very promising, albeit a speculative situation; and willing to give Michael Taylor and Richard Griffiths between them some benefit of the doubt.

Over 1.50 the chart would look very good indeed.

[bigspuds] 05/5/2021 08:21

Lot of small buys this morning

[pdt] 03/5/2021 11:49

Are we due an update on the RP trial?

I think the last presentation said they would give news at key annual conferences and one of them is ARVO which is this week ?? Or did they mean the one in 2022?

The other two mentioned happen in October and November.

[rayrac] 30/4/2021 15:35

Apparently they might get its use extended to other eye problems? That could be a worry.

[dickbush] 30/4/2021 08:19

As you can see, zho. I found the news item and corrected.

Developed by Spark Therapeutics which was acquired by Hoffmann-La Roche for $4.3 billion in December 2019.

[zho] 30/4/2021 08:07

£600,000 cost, not £60,000 according to

"In 2019 the NHS agreed to fund the treatment, Luxturna, the first in a new generation of gene therapies for conditions causing blindness. It costs about £600,000 per patient to treat both eyes, though the NHS has agreed a confidential discount with the makers Novartis."

[dickbush] 30/4/2021 08:03

I saw it, too. As we know, it's for the treatment of a very small percentage of the potential market. Didn't they say the NHS was getting a discount from the normal £600,000 cost of treatment? If anything, that suggests enormous revenue potential for RENE's RP treatment if, IF, the trials go well.

2021 looks like a very important year for RENE.

[philh75] 29/4/2021 19:43

If it’s that bbc article, it’s about luxturna for Lca.

[rayrac] 29/4/2021 19:33

Bit in the news this evening about something similar to rene treatment of the eye. No mention of rene though!

Anyone besides me seen it?

[small crow] 29/4/2021 12:16

A I said, I'm looking for 300p ++

[zho] 29/4/2021 07:33

We have also included the milestones from Fosun for CTX and hRPC. We judge the Company has less control over the timelines for development and we therefore include only the milestones at this stage until more detail is provided. After netting off the corporate expenses and cash, we arrive at a fair value for RENE at 359 pence per share.

[pawelkordala] 29/4/2021 07:23

359p price target from Allenby Capital

[rayrac] 26/4/2021 20:42

Not many follow rene, but it might be worth following it!

[bigspuds] 23/4/2021 14:09

ReNeuron: refinanced and ready to riseThe biotech's recent fundraising and a good chart set-up have tempted Michael Taylor to take a position?April 21, 2021By Michael TaylorFor the second time this week, someone who has never been interested in trading or investing has asked me if they should buy a specific digital coin. Calling tops is a fool's errand. But it's safe to say the top is one day closer than it was yesterday. I've been reading Zero to One by Peter Thiel, in which the dotcom bubble is described as an 18-month frenzy. If we calculate the start of the latest bull run from April 2020, we would still have another six months of glorious speculative madness providing huge amounts of liquidity and volatility. But as we come closer and closer, the spikes go higher along with the risk. Still, we could be in for a fun summer.I have actively started moving capital into small-cap stocks that I believe have potential to weather the inevitable storm. These are uptrending and have strengthening fundamentals – stocks which I would like to add should any fast money exiting present any opportunities. Longer-term positions are now forming a part of my strategy in the stock market along with my active trading strategies that we look at in the column. I'll be posting some of these on Twitter and look forward to hearing any of your thoughts.RENE:LSEReNeuron Group PLC1mthToday change-1.29%Price (GBP)133.75One stock that I have been watching for a while is ReNeuron (RENE), a biotechnology company which researches and develops cell-based therapeutics. Drug companies can be high risk and high reward, but these risks can be mitigated depending on the company's cash position and needs, and where you enter the stock. Many UK biotech boards are poor at raising capital and end up destroying shareholder value after raising less than needed, with the idea of proving up value before raising more money later. This is a good idea in theory, but rarely works in practice. Delays are almost an inevitability and project schedules often shift (even if it is through no fault of the board).Take Phoenix Copper (PXC), which has taken the opposite approach. This is a junior mining company based in the USA, which recently raised money to finance the business with the goal of funding it through to production. The total placing shares were a whopping 73.9 percent of the existing shares – so the total number of shares in issue post placing was not far off double. It's a big dilution pill to stomach. But the advantage here is that it puts to bed any financing worries and secondly gives the board no excuses should they fail to reach production within this timeframe. While there will inevitably be the 10 per cent flippers from the placing, anyone buying now does not need to worry about a placing for the next 12 months, at least. I don't hold this stock, but it is an example of good management, in my view.ReNeuron decided to go to the market and raise £15 million last November. This gives them a runway of around 18 months – similarly ample time to get on with the job of creating value for shareholders without the worry and distraction of conducting That has not always been the case, as Chart 1 shows the stock trending sideways after a multi-year fall from 640p in 2015. I have marked with an arrow underneath a volume spike, which shows the stock rising on large volume. Perhaps this was a seller clearing and being transferred, or several trades being dealt on the back of positive news, however the stock burst through the pink 200-day exponential moving average (EMA) and formed a bull flag over the coming sessions.A bull flag is where the price consolidates sideways after a big rise, and so the rise candle is the mast, with the flag being formed in the consolidation. These are also known as pennants if the price volatility declines.We can see in Chart 1 that the stock retested the 200-day EMA resistance as support several times. This gave traders confidence that the stock was making a new trend, and I've marked the arrow when the stock broke out through this resistance. We can also see an increase of volume around this period, which was demand driving the price higher.Those that took this trade (sadly I didn't) will have made a nice multi-R gain if they had run the winner, as the stock surged 50 per cent before pausing for breath and resuming. You never know which trades will be your big winners, but by aiming to squeeze out as much juice as possible out of a trade you increase your chances of delivering high R payouts.?Moving across to Chart 2, I've marked the point with the top arrow the date where the company placed new equity at 70p. We can see in the prior months the stock selling off due to the knowledge that a placing was soon on the horizon – this is one advantage of a well-financed business, as there are no worries and therefore little stock price slippage due to people selling with the intention of reloading cheaper in the placing. The second arrow below shows the volume spike and increase in volume since that placing through the first quarter of 2021.I currently hold a position in ReNeuron, and I want to add to this should the stock break out of the 140p resistance zone. We can see a scruffy cup and handle forming on the chart which is my favourite pattern. I have no idea about the company's prospects, but the recent placing and chart combination gives me the confidence to take the trade. As with all non-profitable pharmaceutical companies it must come with a wealth warning, but for those looking to capture speculative upside in this sector I feel this could be a good entry point.Michael has started his Buy the Breakout newsletter which contains trading ideas and tips he has learned whilst trading. You can subscribe for free at his website here: www.shiftingshares.com/newsletter/Twitter: @shiftingsharesNew subscribers to SharePad can claim a free month of data with the code: Michael Explore TopicsIdeasInvestment IdeasMore on Investment Ideas?April 22, 2021Big director share sales this week?April 22, 2021Macfarlane ticks the right boxes?April 22, 2021Intuitive Surgical: a cut above??April 22, 2021Ideas Farm: Infuriating intangiblesMore on Ideas?April 23, 2021Momentum investing stops working?April 22, 2021Big director share sales this week?April 22, 2021Macfarlane ticks the right boxes?April 22, 2021Intuitive Surgical: a cut above?FOLLOW US:Contact UsAbout UsHelpNearest Stockist

[stewart_25] 23/4/2021 11:37

what does the recommendation state? any mention of suggest share price ?

[bradders51] 23/4/2021 11:17

Mention and recommendation in IC.

[small crow] 22/4/2021 14:27

"Chart suggests a break of 150 will be followed by a rapid move up to 200+"

I'm thinking more like 200 +++ long term.

[pawelkordala] 22/4/2021 12:34

SP reacting to LinkedIn post confirming Barcelona site opening

[someuwin] 22/4/2021 10:51

Chart suggests a break of 150 will be followed by a rapid move up to 200+.

[rayrac] 22/4/2021 10:49

I keep my tabs on this and the chart..could be ‘huge’